For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) ...

All doses of Novo Nordisk's popular GLP-1 medicines Ozempic and Wegovy are available in the U.S. and being regularly shipped ...

The start-up rebranded itself as Hyntelo, complete with new name and logo. The name Hyntelo is ... leading pharmaceutical companies such as MSD, Novo Nordisk, Grünenthal and Takeda rely on ...

An array of pharmaceutical pills with the company's logo on the bottle. Regarding Eli Lilly and Company ... The pricing for ...

Luxury brands are so-called Veblen goods: a category of consumer products that inverts the usual laws of economics. Instead of crimping demand when prices rise, luxury goods can become more ...

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has disclosed recent transactions involving the purchase of 1,300 American Depositary Receipts (ADRs) by its board members and executives. This ...